Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 214Lung Neoplasms 74Neoplasms 24Adenocarcinoma of Lung 16Neoplasm Metastasis 15Mesothelioma, Malignant 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma 12Carcinoma 11Head and Neck Neoplasms 10Breast Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Recurrence 5Pancreatic Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Lung Diseases 3Laryngeal Diseases 3Carcinoma, Small Cell 3Brain Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Solitary Fibrous Tumor, Pleural 2

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Non Small Cell Lung Carcinoma NSCLC × Pemetrexed × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡